Dermatology

Dupilumab is the first and only medicine approved specifically for the treatment of prurigo nodularis in the United States.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Deucravacitinib is a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, which is a member of the Janus kinase (JAK) family.

Alopecia areata is an autoimmune disease with an underlying immuno-inflammatory pathogenesis.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.

Neutrogena On-the-Spot with benzoyl peroxide helps reduce treat acne breakouts.

Triple Paste Ointment is used to treat rashes, including diaper rash.

Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.

Researchers discovered that a common anti-inflammatory drug could lower the number of patients on ventilators from COVID-19, increasing the likelihood of survival by more than 50%.

Guidelines provide information on the management and treatment of this common skin condition.

Campho-Phenique is an antiseptic liquid indicated for the treatment of insect bites, minor skin irritations, and minor burns.

Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13Rα1 and IL-4Rα, which blocks downstream signal activation along the IL-13 pathway.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Calazime is indicated for the treatment and prevention of diaper rash and minor skin irritations.

Daptomycin for injection (Cubicin) is indicated for the treatment of complicated skin and skin structure infections and Staphylococcus aureus bloodstream infections.

SilverSeal provides topical management of minor superficial wounds, lacerations, and abrasions, as well as minor first-degree burns.

Dermala helps support hormonal balance, which may help in the treatment of acne.

Ustekinumab is the first and only biologic that targets both cytokines interleukin (IL)-12 and IL-23.

Topical symptomatic relief for resistant skin conditions, including severe boils, hemorrhoids, eczema, cold sores, fungal infections, psoriasis, poison ivy, oak and sumac, and other itchy, painful conditions.

Tapinarof (Vtama) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

AfterBurn gel offers relief for sunburn, scalds, and other types of burns.

People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.

Alocane provides fast pain relief and helps the healing process from minor burns.

Tapinarof is a first-in-class topical steroid-free aryl hydrocarbon receptor antagonist intended to mitigate the symptoms of plaque psoriasis.

TriDerma Eczema Fast Healing helps sooth dry and irritated skin for itch relief.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Ruxolitinib (Opzelura; Incyte) cream 1.5% is the first and only treatment approved by the FDA for repigmentation in patients with vitiligo.